{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:17:13Z","timestamp":1794107833504,"version":"4.8.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NP-107-PP-05"],"award-info":[{"award-number":["NP-107-PP-05"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.biopha.2021.112369","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T22:29:18Z","timestamp":1635287358000},"page":"112369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Betaine prevents and reverses the behavioral deficits and synaptic dysfunction induced by repeated ketamine exposure in mice"],"prefix":"10.1016","volume":"144","author":[{"given":"Shao-Tsu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Pin","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Yi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liao-Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwei-Hsien","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Huan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2021.112369_bib1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2021.112369_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.biopha.2021.112369_bib3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2021.112369_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4088\/JCP.17m11731","article-title":"Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric Hospital","volume":"79","author":"Wilkinson","year":"2018","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.biopha.2021.112369_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1360-0443.2009.02761.x","article-title":"Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study","volume":"105","author":"Morgan","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.biopha.2021.112369_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fpsyt.2014.00149","article-title":"Long-term heavy ketamine use is associated with spatial memory impairment and altered hippocampal activation","volume":"5","author":"Morgan","year":"2014","journal-title":"Front Psychiatry"},{"issue":"17","key":"10.1016\/j.biopha.2021.112369_bib7","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1007\/s00213-016-4359-x","article-title":"Betaine enhances antidepressant-like, but blocks psychotomimetic effects of ketamine in mice","volume":"233","author":"Lin","year":"2016","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2021.112369_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.biochi.2018.01.002","article-title":"Glycine betaine rather than acting only as an osmolyte also plays a role as regulator in cellular metabolism","volume":"147","author":"Figueroa-Soto","year":"2018","journal-title":"Biochimie"},{"issue":"42","key":"10.1016\/j.biopha.2021.112369_bib9","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1021\/acs.jafc.6b03592","article-title":"Antioxidant mechanism of betaine without free radical scavenging ability","volume":"64","author":"Zhang","year":"2016","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.biopha.2021.112369_bib10","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3389\/fimmu.2018.01070","article-title":"Betaine in inflammation: mechanistic aspects and applications","volume":"9","author":"Zhao","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2021.112369_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/molecules24020367","article-title":"Effects of betaine on LPS-stimulated activation of microglial M1\/M2 phenotypes by suppressing TLR4\/NF-kappaB pathways in N9 cells","volume":"24","author":"Shi","year":"2019","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.biopha.2021.112369_bib12","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0016-5085(03)00276-2","article-title":"Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice","volume":"124","author":"Ji","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2021.112369_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.exer.2012.12.001","article-title":"Betaine stabilizes cell volume and protects against apoptosis in human corneal epithelial cells under hyperosmotic stress","volume":"108","author":"Garrett","year":"2013","journal-title":"Exp. Eye Res."},{"issue":"11","key":"10.1016\/j.biopha.2021.112369_bib14","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/archneur.1984.04050220023004","article-title":"N,N-dimethylglycine, betaine, and seizures","volume":"41","author":"Freed","year":"1984","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112369_bib15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0091-3057(85)90288-6","article-title":"Prevention of strychnine-induced seizures and death by the N-methylated glycine derivatives betaine, dimethylglycine and sarcosine","volume":"22","author":"Freed","year":"1985","journal-title":"Pharm. Biochem Behav."},{"issue":"4","key":"10.1016\/j.biopha.2021.112369_bib16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0091-3057(85)90287-4","article-title":"Effects of betaine on seizures in the rat","volume":"22","author":"Ghoz","year":"1985","journal-title":"Pharm. Biochem Behav."},{"issue":"1","key":"10.1016\/j.biopha.2021.112369_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4062\/biomolther.2012.072","article-title":"Antidepressant-like effects of lycii radicis cortex and betaine in the forced swimming test in rats","volume":"21","author":"Kim","year":"2013","journal-title":"Biomol. Ther. (Seoul. )"},{"key":"10.1016\/j.biopha.2021.112369_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1742-2094-8-153","article-title":"Effects of betaine on lipopolysaccharide-induced memory impairment in mice and the involvement of GABA transporter 2","volume":"8","author":"Miwa","year":"2011","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.biopha.2021.112369_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbr.2015.06.004","article-title":"Betaine prevents homocysteine-induced memory impairment via matrix metalloproteinase-9 in the frontal cortex","volume":"292","author":"Kunisawa","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.biopha.2021.112369_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejphar.2016.12.007","article-title":"Betaine attenuates memory impairment after water-immersion restraint stress and is regulated by the GABAergic neuronal system in the hippocampus","volume":"796","author":"Kunisawa","year":"2017","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2021.112369_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neulet.2015.11.019","article-title":"Betaine reverses the memory impairments in a chronic cerebral hypoperfusion rat model","volume":"615","author":"Nie","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biopha.2021.112369_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.neuroscience.2021.08.004","article-title":"N, N-dimethylglycine protects behavioral disturbances and synaptic deficits induced by repeated ketamine exposure in mice","volume":"472","author":"Hsieh","year":"2021","journal-title":"Neuroscience"},{"issue":"17","key":"10.1016\/j.biopha.2021.112369_bib23","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1007\/s00213-015-3973-3","article-title":"The group II metabotropic glutamate receptor agonist LY379268 reduces toluene-induced enhancement of brain-stimulation reward and behavioral disturbances","volume":"232","author":"Chan","year":"2015","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2021.112369_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pnpbp.2016.06.002","article-title":"N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice","volume":"71","author":"Lin","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2021.112369_bib25","first-page":"1","article-title":"Differential inhibitory effects of resveratrol on excitotoxicity and synaptic plasticity: involvement of NMDA receptor subtypes","volume":"24","author":"Hsieh","year":"2019","journal-title":"Nutr. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2021.112369_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0165-0270(99)00113-2","article-title":"A new planar multielectrode array for extracellular recording: application to hippocampal acute slice","volume":"93","author":"Oka","year":"1999","journal-title":"J. Neurosci. Methods"},{"issue":"4","key":"10.1016\/j.biopha.2021.112369_bib27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881113512909","article-title":"Reviewing the ketamine model for schizophrenia.","volume":"28","author":"Frohlich","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112369_bib28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2174\/1389201019666180620112528","article-title":"Glutamatergic deficits in schizophrenia - biomarkers and pharmacological interventions within the ketamine model","volume":"19","author":"Haaf","year":"2018","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112369_bib29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.brainresrev.2008.07.006","article-title":"The acute effects of NMDA antagonism: from the rodent to the human brain","volume":"60","author":"Gunduz-Bruce","year":"2009","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.biopha.2021.112369_bib30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.brainresbull.2017.11.007","article-title":"CaMKIIalpha expression in a mouse model of NMDAR hypofunction schizophrenia: Putative roles for IGF-1R and TLR4","volume":"137","author":"Ogundele","year":"2018","journal-title":"Brain Res. Bull."},{"issue":"6","key":"10.1016\/j.biopha.2021.112369_bib31","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00213-015-4181-x","article-title":"The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like behaviour in rats","volume":"233","author":"Trevlopoulou","year":"2016","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"3","key":"10.1016\/j.biopha.2021.112369_bib32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharm. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2021.112369_bib33","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.pnpbp.2012.04.018","article-title":"Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia","volume":"38","author":"Chindo","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.biopha.2021.112369_bib34","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/npp.2016.202","article-title":"GLYX-13 produces rapid antidepressant responses with key synaptic and behavioral effects distinct from ketamine","volume":"42","author":"Liu","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.biopha.2021.112369_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.biopha.2021.112369_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0893-133X(98)00067-0","article-title":"Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis","volume":"20","author":"Newcomer","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.biopha.2021.112369_bib37","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.biopsych.2012.05.009","article-title":"Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia","volume":"72","author":"D\u2019Souza","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.biopha.2021.112369_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0893-133X(97)00036-5","article-title":"Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics","volume":"17","author":"Malhotra","year":"1997","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.biopha.2021.112369_bib39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"10.1016\/j.biopha.2021.112369_bib40","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00213-014-3782-0","article-title":"Chronic administration of ketamine mimics the perturbed sense of body ownership associated with schizophrenia","volume":"232","author":"Tang","year":"2015","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.biopha.2021.112369_bib41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.schres.2018.02.049","article-title":"Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia","volume":"199","author":"Cheng","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.biopha.2021.112369_bib42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fnana.2013.00023","article-title":"Brain damages in ketamine addicts as revealed by magnetic resonance imaging","volume":"7","author":"Wang","year":"2013","journal-title":"Front Neuroanat."},{"issue":"1","key":"10.1016\/j.biopha.2021.112369_bib43","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.biopsych.2010.08.030","article-title":"Reduced dorsal prefrontal gray matter after chronic ketamine use","volume":"69","author":"Liao","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2021.112369_bib44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fnins.2017.00285","article-title":"Chronic ketamine exposure causes white matter microstructural abnormalities in adolescent cynomolgus monkeys","volume":"11","author":"Li","year":"2017","journal-title":"Front Neurosci."},{"key":"10.1016\/j.biopha.2021.112369_bib45","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ynstr.2018.09.001","article-title":"On the safety of repeated ketamine infusions for the treatment of depression: effects of sex and developmental periods","volume":"9","author":"Strong","year":"2018","journal-title":"Neurobiol. Stress"},{"issue":"5994","key":"10.1016\/j.biopha.2021.112369_bib46","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"issue":"Pt A","key":"10.1016\/j.biopha.2021.112369_bib47","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neuropharm.2016.05.010","article-title":"Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB\/cJ mice","volume":"112","author":"Pham","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2021.112369_bib48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2019.02.017","article-title":"Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies","volume":"199","author":"Pham","year":"2019","journal-title":"Pharm. Ther."},{"issue":"17","key":"10.1016\/j.biopha.2021.112369_bib49","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"issue":"10","key":"10.1016\/j.biopha.2021.112369_bib50","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1017\/S1461145713000722","article-title":"Serotonergic hallucinogens as translational models relevant to schizophrenia","volume":"16","author":"Halberstadt","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112369_bib51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1254\/jphs.12148SC","article-title":"Involvement of serotonin receptor mechanisms in the discriminative stimulus effects of ketamine in rats","volume":"121","author":"Yoshizawa","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2021.112369_bib52","first-page":"699","article-title":"Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats","volume":"282","author":"Willins","year":"1997","journal-title":"J. Pharm. Exp. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2021.112369_bib53","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF02976533","article-title":"NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in PCPA-treated mice","volume":"22","author":"Kim","year":"1999","journal-title":"Arch. Pharm. Res."},{"issue":"8","key":"10.1016\/j.biopha.2021.112369_bib54","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.biopha.2021.112369_bib55","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/s41386-018-0136-3","article-title":"The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects","volume":"43","author":"Abdallah","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2021.112369_bib56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fncel.2017.00181","article-title":"Glutamate deregulation in ketamine-induced psychosis-a potential role of PSD95, NMDA receptor and PMCA interaction","volume":"11","author":"Lisek","year":"2017","journal-title":"Front Cell Neurosci."},{"issue":"10","key":"10.1016\/j.biopha.2021.112369_bib57","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2021.112369_bib58","first-page":"53","article-title":"[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine]","volume":"27","author":"Mechri","year":"2001","journal-title":"Encephale"},{"issue":"3","key":"10.1016\/j.biopha.2021.112369_bib59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/0269881107077712","article-title":"Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?","volume":"21","author":"Large","year":"2007","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112369_bib60","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.neubiorev.2008.03.012","article-title":"Models of schizophrenia in humans and animals based on inhibition of NMDA receptors","volume":"32","author":"Buben\u00edkov\u00e1-Valesov\u00e1","year":"2008","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.biopha.2021.112369_bib61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuropharm.2013.01.001","article-title":"Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis","volume":"74","author":"Wiescholleck","year":"2013","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.biopha.2021.112369_bib62","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.euroneuro.2013.09.011","article-title":"Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans","volume":"24","author":"Neill","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112369_bib63","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/npp.2011.295","article-title":"Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence","volume":"37","author":"D\u2019Souza","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.biopha.2021.112369_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177036","article-title":"Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation","volume":"12","author":"Rame","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2021.112369_bib65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0006-8993(83)91244-1","article-title":"Elimination of long-term potentiation in the hippocampus by phencyclidine and ketamine","volume":"258","author":"Stringer","year":"1983","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2021.112369_bib66","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainres.2014.03.004","article-title":"Clinically relevant concentrations of ketamine mainly affect long-term potentiation rather than basal excitatory synaptic transmission and do not change paired-pulse facilitation in mouse hippocampal slices","volume":"1560","author":"Ribeiro","year":"2014","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.biopha.2021.112369_bib67","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/0006-8993(92)91273-H","article-title":"Ketamine blocks the induction of LTP at the lateral entorhinal cortex-dentate gyrus synapses","volume":"593","author":"Zhang","year":"1992","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.biopha.2021.112369_bib68","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11571-018-9474-4","article-title":"Neonatal exposure of ketamine inhibited the induction of hippocampal long-term potentiation without impairing the spatial memory of adult rats","volume":"12","author":"Guo","year":"2018","journal-title":"Cogn. Neurodyn"},{"key":"10.1016\/j.biopha.2021.112369_bib69","article-title":"Chronic administration of ketamine induces cognitive deterioration by restraining synaptic signaling","author":"Luo","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.biopha.2021.112369_bib70","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.neuropharm.2008.08.018","article-title":"A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus","volume":"55","author":"Zhang","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2021.112369_bib71","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bbr.2015.07.039","article-title":"Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats","volume":"294","author":"Burgdorf","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.biopha.2021.112369_bib72","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbr.2015.10.060","article-title":"GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice","volume":"299","author":"Rajagopal","year":"2016","journal-title":"Behav. Brain Res."}],"updated-by":[{"DOI":"10.1016\/j.biopha.2023.114840","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000}}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T23:56:58Z","timestamp":1686873418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221011537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":72,"alternative-id":["S0753332221011537"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112369","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Betaine prevents and reverses the behavioral deficits and synaptic dysfunction induced by repeated ketamine exposure in mice","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112369"}}